

Company registration number: 435571

Drimoleague Pharmacy Limited
Unaudited abridged financial statements
for the financial year ended 31 December 2025

Drimoleague Pharmacy Limited

Contents

	Page
Directors responsibilities statement	1
Accountants report	2
Balance sheet	3 - 4
Notes to the abridged financial statements	5 - 11

Drimoleague Pharmacy Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Drimoleague Pharmacy Limited

Accountants' Report to the board of directors on the Unaudited abridged financial statements of Drimoleague Pharmacy Limited

In accordance with the engagement letter, and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled the financial statements which comprise the , balance sheet and related notes from the accounting records and information and explanations you have given to us.

This report is made to the company's board of directors, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's board of directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's board of directors for our work or for this report.

We have carried out this engagement in accordance with guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the balance sheet for the financial year ended 31 December 2025 your duty under the Companies Act 2014 to ensure that the company has kept adequate accounting records and prepared financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for that financial year, and otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company. You consider that the company is exempt from the statutory requirement for an audit for the financial year.

We have not been instructed to carry out an audit of the financial statements. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

Barrett O'Connor & Co.

Chartered Accountants

Unit 7

Kilnap Business & Technology Park

Mallow Road

Cork

Date: 13 March 2026

Drimoleague Pharmacy Limited

**Balance sheet
As at 31 December 2025**

	Note	2025 €	€	2024 €	€
Fixed assets					
Intangible assets	6	58,500		87,750	
Tangible assets	7	18,627		25,952	
			77,127		113,702
Current assets					
Stocks	8	123,498		103,291	
Debtors	9	97,356		82,163	
Cash at bank and in hand		7,322		2,030	
		228,176		187,484	
Creditors: amounts falling due within one year					
	10	(250,662)		(215,408)	
Net current liabilities			(22,486)		
Total assets less current liabilities			54,641	(27,924)	
Net assets			54,641	85,778	
Capital and reserves					
Called up share capital presented as equity			2		2
Profit and loss account			54,639		85,776
Shareholders funds			54,641	85,778	

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 5 to 11 form part of these abridged financial statements.

Drimoleague Pharmacy Limited

**Balance sheet (continued)
As at 31 December 2025**

We, as directors of Drimoleague Pharmacy Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 13 March 2026 and signed on behalf of the board by:

Sinead Crowley
Director

Richard DeBarbouille
Director

The notes on pages 5 to 11 form part of these abridged financial statements.

Drimoleague Pharmacy Limited

Notes to the abridged financial statements Financial year ended 31 December 2025

1. General information

The company is a private company limited by shares, registered in the Republic of Ireland. The address of the registered office is Main Street, Drimoleague, Co. Cork.

2. Accounting policies and measurement bases

Basis of preparation

The financial statements are prepared on the going concern basis, under the historical cost convention.

The financial statements are prepared in Euro which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Goodwill - 5 % straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 December 2025

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Plant and machinery	- 15%	straight line
Fittings fixtures and equipment	- 15%	straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 December 2025

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 December 2025

3. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 13 (2024: 13).

The aggregate payroll costs incurred during the financial year were:

	2025	2024
	€	€
Wages and salaries	271,747	238,717
Social insurance costs	24,520	21,045
Other retirement benefit costs	12,618	12,779
	<u>308,885</u>	<u>272,541</u>

4. Directors remuneration

The directors aggregate remuneration was as follows:

	2025	2024
	€	€
Emoluments in respect of qualifying services	74,072	76,666
Pension contributions to defined contribution plans in respect of qualifying services	12,618	12,779
	<u>86,690</u>	<u>89,445</u>

5. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	85,776	119,396
Loss for the financial year	(31,137)	(33,620)
At the end of the financial year	<u>54,639</u>	<u>85,776</u>

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 December 2025

6. Intangible assets		Goodwill	Total	
		€	€	
Cost				
At 1 January 2025 and 31 December 2025		585,000	585,000	
Amortisation				
At 1 January 2025		497,250	497,250	
Charge for the financial year		29,250	29,250	
At 31 December 2025		526,500	526,500	
Carrying amount				
At 31 December 2025		58,500	58,500	
At 31 December 2024		87,750	87,750	
7. Tangible assets			Total	
	Plant and machinery	Fixtures, fittings and equipment	Motor vehicles	€
	€	€	€	€
Cost				
At 1 January 2025 and 31 December 2025	254,160	199,363	11,000	464,523
Depreciation				
At 1 January 2025	254,160	181,661	2,750	438,571
Charge for the financial year	-	5,950	1,375	7,325
At 31 December 2025	254,160	187,611	4,125	445,896
Carrying amount				
At 31 December 2025	-	11,752	6,875	18,627
At 31 December 2024	-	17,702	8,250	25,952
8. Stocks			2025	2024
			€	€
Finished goods and goods for resale			123,498	103,291

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 December 2025

9. Debtors

	2025	2024
	€	€
Trade debtors	63,240	52,991
Other debtors	32,546	27,587
Prepayments	1,570	1,585
	97,356	82,163

10. Creditors: amounts falling due within one year

	2025	2024
	€	€
Amounts owed to credit institutions	35,346	8,538
Trade creditors	102,204	76,769
Other creditors including tax and social insurance	109,612	126,601
Accruals	3,500	3,500
	250,662	215,408

11. Directors transactions

During the financial year the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	2025	2024
	€	€
At the start of the financial year	118,330	122,484
Amounts repaid during the financial year	(16,811)	(4,154)
At the end of the financial year	101,519	118,330

Disclosure for each director or other person is as follows:

Sinead Crowley

Directors Loan Account

	2025	2024
	€	€
At the start of the financial year	118,330	122,484
Amounts repaid during the financial year	(16,811)	(4,154)
At the end of the financial year	101,519	118,330

This loan is provided on an interest free basis and is repayable on demand.

Drimoleague Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 December 2025

12. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 13 March 2026.